Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jado Technologies, a developer of RAFT intervention therapeutics, has announced positive results from a Phase IIa clinical trial of its lead RAFT modulator TF002 in patients with severe atopic dermatitis.
Subscribe to our email newsletter
The randomized, double-blind, active (hydrocortisone) controlled, 17 patient study demonstrated that TF002 met its primary endpoint of significant reduction of inflammation in atopic skin. The anti-inflammatory effect was measured through a highly significant improvement in TIS (Three Item Severity) score after three week treatment. Both TF002 and hydrocortisone achieved an improvement of the TIS score of more than 1.5 which was defined as being clinical efficacious. TF002 appeared to have longer-lasting effects in a four weeks follow-on examination and did not induce skin atrophy compared to hydrocortisone, which was measured as a secondary outcome. TF002 showed a trend of reducing total number of mast cells.
Charl van Zyl, CEO of Jado Technologies, said: “We believe that targeting RAFTS in allergic diseases could potentially lead to effective new treatments without the side effects commonly seen with currently available therapies.”